HOME >> BIOLOGY >> NEWS
U OF M awarded $22.5 million NIH contract to study avian influenza

The National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), today named the University of Minnesota as one of six sites across the country that will establish a Center of Excellence for Influenza Research and Surveillance.

The Minnesota NIH/NIAID Center of Excellence for Influenza Research and Surveillance (MCEIRS) will receive $22.5 million over seven years to focus on disease and virologic surveillance of avian influenza viruses, providing the federal government with useful information and public health strategies for controlling the impact of an influenza pandemic.

The Center of Excellence established at the U of M will work to rapidly identify and characterize influenza viruses that have pandemic potential by monitoring domestic and international wild bird, poultry, and swine populations, said Marguerite Pappaioanou, D.V.M., Ph.D., principal investigator and professor of infectious disease and epidemiology at the University of Minnesota School of Public Health. The center will be prepared to respond to research and public health needs in a time of increasing concern over the possibility of pandemic flu.

The MCEIRS will perform animal flu surveillance in eight countries and multiple states. Domestic research will include: monitoring wild birds in U.S. wetlands; identifying low pathologic influenza strains in Minnesota poultry; characterizing swine viruses in animal populations from Minnesota to North Carolina; and conducting virologic surveillance in live bird markets in the Midwest and Northeast. Internationally, the center will conduct avian influenza surveillance of people, poultry, pigs, dogs, cats, and wild birds in rural Thailand; wild waterfowl in Vietnam; wild bird populations in Laos; and commercial poultry operations in other Asian countries.

The majority of diagnostic testing and virus characterization will occur at the University of Minnesota College of Veterinary Medici
'"/>

Contact: Liz Wulderk
ebryan@umn.edu
612-624-5680
University of Minnesota
2-Apr-2007


Page: 1 2 3

Related biology news :

1. Jan Lwe awarded 2007 EMBO Gold Medal
2. $9M grant awarded to University of Cincinnati for bipolar disorder research
3. Cancer research specialist and HSPH professor awarded Medal of Honor from WHO cancer agency
4. CSHL awarded Pre-College Science Education Grant by HHMI
5. UD awarded $11M for osteoarthritis research and unique mentoring program for women scientists
6. UC Irvine awarded $3.9 million to upgrade stem cell research facilities, training
7. Computer science professor awarded $400,000 from National Science Foundation
8. Ocean observing contracts awarded to UC San Diego and University of Washington
9. Jaap Sinninghe Damst awarded the Vernadsky Medal for innovative use of biomarkers
10. Berkeley Lab Life Sciences division awarded NIH grants for fruit fly, nematode studies
11. Case Western Reserve University School of Medicine researchers awarded $27M for TB research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: awarded million NIH contract study avian influenza

(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
Cached News: